Upstream regains access to its laboratories following COVID-19 lockdown

Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.

The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.

By shifting chest pain patients with intermediate troponins to low or high-risk categories, Marker C could rapidly triage 10-35% more chest pain patients in the emergency department.